clinical trial · NCT04802837
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Clostridioides Difficile InfectionRidinilazoleVancomycin
brief summary
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
started
May 19, 2021
primary completion
Sep 17, 2021
completion
Sep 28, 2022
last updated
Aug 21, 2023
official title
A Randomized, Double Blind, Active Controlled Study to Evaluate the Safety and Tolerability of Ridinilazole Compared With Vancomycin and to Assess the Pharmacokinetics of Ridinilazole in Adolescent Subjects (Aged 12 to <18 Years) With Clostridioides Difficile Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol